Highly-specific memory B cells generation after the 2nd dose of BNT162b2 vaccine compensate for the decline of serum antibodies and absence of mucosal IgA

  1. Eva Piano Mortari
  2. Cristina Russo
  3. Maria Rosaria Vinci
  4. Sara Terreri
  5. Ane Fernandez Salinas
  6. Livia Piccioni
  7. Claudia Alteri
  8. Luna Colagrossi
  9. Luana Coltella
  10. Stefania Ranno
  11. Giulia Linardos
  12. Marilena Agosta
  13. Christian Albano
  14. Chiara Agrati
  15. Concetta Castilletti
  16. Silvia Meschi
  17. Paolo Romania
  18. Giuseppe Roscilli
  19. Emiliano Pavoni
  20. Vincenzo Camisa
  21. Annapaola Santoro
  22. Rita Brugaletta
  23. Nicola Magnavita
  24. Alessandra Ruggiero
  25. Nicola Cotugno
  26. Donato Amodio
  27. Marta Luisa Ciofi Degli Atti
  28. Daniela Giorgio
  29. Nicoletta Russo
  30. Guglielmo Salvatori
  31. Tiziana Corsetti
  32. Franco Locatelli
  33. Carlo Federico Perno
  34. Salvatore Zaffina
  35. Rita Carsetti
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Specific memory B cells and antibodies are reliable read-out of vaccine efficacy. We analyzed these biomarkers after one and two doses of BNT162b2 vaccine. The second dose significantly increases the level of highly-specific memory B cells and antibodies. Two months after the second dose, specific antibody levels decline, but highly specific memory B cells continue to increase thus predicting a sustained protection from COVID-19. <fig id="ufig1" position="float" orientation="portrait" fig-type="figure"><caption>

Graphical Abstract

</caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="21258284v1_ufig1" position="float" orientation="portrait"/></fig>

Related articles

Related articles are currently not available for this article.